Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 September 2019 | Story Ruan Bruwer | Photo Varsity Sports
Netball
Jana Scholtz, goal defender and playing in her first year as a regular starter, has been a solid performer for the Kovsie netball team in Varsity Netball.

The building blocks are starting to form a solid basis from where Kovsies can launch an attack to defend the Varsity Netball title they won in 2018. This is according to Karin Venter, one of the team’s assistant coaches.

After losing their first encounter to Tuks, they registered wins over the University of Johannesburg, Tshwane University of Technology, and the North-West University. The match against the Maties in Bloemfontein on 23 September 2019 – the last in the group stage, should determine which of the two teams will book a home semi-final along with Tuks.

“Yes, that is the crucial one,” said Venter, the team’s defensive coach. Her counterpart at the Maties is Adéle Niemand, with whom Venter combined as defenders at Kovsies for several matches in the mid-2000s. Apart from the Maties, the women of the University of the Free State still have to face the Madibaz and the University of the Western Cape (both in Pretoria on 15 and 16 September 2019).

“The combinations are starting to form a unit and our confidence is on the increase. Now we are looking for consistency in our performances.”

According to Venter, they were hit hard by goalkeeper Ané Retief’s injury, which kept her out of the first two matches. This meant that they had to start against Tuks with a first-year student, Chanel Vrey.

“It was tough, but I’m impressed with the way in which she, Ancia Pienaar, and Jana Scholtz – who are all youngsters – stepped up.”

Venter is responsible for the analyses and recons to assist players.

“The programme we are using provides us with all the required footage. You can make notes on it and send these clips to players, which means you don’t have to sit next to a player to explain something. We also provide them with notes and sketches of opponents’ playing patterns, which they must work through as part of their preparation.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept